Version 1
: Received: 16 October 2023 / Approved: 17 October 2023 / Online: 18 October 2023 (11:44:35 CEST)
How to cite:
Ma, H.; Chen, Q. Comparison and Analysis of Clinical Efficacy and Safety between Monotherapy and Dual Therapy in the Treatment of Early Ischemic Stroke. Preprints2023, 2023101174. https://doi.org/10.20944/preprints202310.1174.v1
Ma, H.; Chen, Q. Comparison and Analysis of Clinical Efficacy and Safety between Monotherapy and Dual Therapy in the Treatment of Early Ischemic Stroke. Preprints 2023, 2023101174. https://doi.org/10.20944/preprints202310.1174.v1
Ma, H.; Chen, Q. Comparison and Analysis of Clinical Efficacy and Safety between Monotherapy and Dual Therapy in the Treatment of Early Ischemic Stroke. Preprints2023, 2023101174. https://doi.org/10.20944/preprints202310.1174.v1
APA Style
Ma, H., & Chen, Q. (2023). Comparison and Analysis of Clinical Efficacy and Safety between Monotherapy and Dual Therapy in the Treatment of Early Ischemic Stroke. Preprints. https://doi.org/10.20944/preprints202310.1174.v1
Chicago/Turabian Style
Ma, H. and Qiming Chen. 2023 "Comparison and Analysis of Clinical Efficacy and Safety between Monotherapy and Dual Therapy in the Treatment of Early Ischemic Stroke" Preprints. https://doi.org/10.20944/preprints202310.1174.v1
Abstract
Objective: To analyze the clinical efficacy and safety of monotherapy and dual therapy in patients with early ischemic stroke. Methods: The study was conducted from August 2020 to August 2021, and 80 patients with early ischemic stroke who received treatment at our hospital during this period were selected as the study population. They were randomly divided into a control group and an observation group, with 40 patients in each group. The control group received conventional monotherapy, while the observation group received conventional dual therapy. The efficacy and safety indicators of the two groups were compared.Results: The treatment efficacy, functional recovery, blood indicators, and inflammation markers in the observation group were all superior to those in the control group (all, P<0.05); there was no significant difference in the drug safety profile between the two groups (P>0.05).Conclusion: The dual antiplatelet therapy is more ideal than monotherapy for treating patients with early ischemic stroke. It can further promote the recovery of neurological and cognitive function, improve hematological and inflammatory response indicators in patients, and the safety of this regimen is comparable to monotherapy.
Keywords
monotherapy; dual therapy; early ischemic stroke; efficacy; safety
Subject
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
